High percentage of JAK2 exon 12 mutation in asian patients with polycythemia vera

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 266-270

  Yeh, Yu Min ^a   Chen, Yi Lin ^b   Cheng, Hsieh Yin ^b   Su, Wu Chou ^a   Chow, Nan Haw ^b   Chen, Tsai Yun ^a   Ho, Chung Liang ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Exon 12 mutation; JAK2V617F; Polycythemia vera; Taiwan

Indexed keywords

ASPARAGINE; GLUTAMIC ACID; ISOLEUCINE; JANUS KINASE 2; LYSINE; PHENYLALANINE; VALINE;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; EXON; FEMALE; GENE DELETION; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; LEUKOCYTE COUNT; MALE; MEDICAL LITERATURE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK ASSESSMENT; TAIWAN; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; TAIWAN;

EID: 77955595265     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPK7KGOWPHYWM0     Document Type: Article

References (20)

1. Thiele J, Kvasnicka HM, Orazi A, et al. Polycythemia vera. In: Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:40-43.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148. (Pubitemid 40663494)
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. (Pubitemid 40570926)
5. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med. 2008;59:213-222.
6. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
7. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009;11:49-53.
8. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686-1689.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
10. Lieu CH, Wu HS, Hon YC, et al. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Intern Med J. 2008;38:422-426.
11. V617F mutation in Chinese patients with myeloproliferative disorders. Am J Hematol. 2007;82:458-459.
12. V617F-negative polycythaemia vera patients. Leukemia. 2008;22:870-873.
13. Williams DM, Kim AH, Rogers O, et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35:1641-1646.
14. V617F-negative polycythemia vera. Leukemia. 2007;21:1960-1963.
15. Kouroupi E, Zoi K, Parquet N, et al. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. Br J Haematol. 2008;142:676-679.
16. Martínez-Avilés L, Besses C, Alvarez-Larrán A, et al. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica. 2007;92:1717-1718.
17. Bernardi M, Ruggeri M, Albiero E, et al. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation. Am J Hematol. 2009;84:258-260.
18. Zhang X, Chang A. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet. 2007;44:166-172.
19. Li S, Kralovics R, De Libero G, et al. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008;111:3863-3866.
20. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-846.